3-[2-((2S)-2-cyano-pyrrolidin-1-yl)-2-oxo-ethylamino]-3-methyl-butyramide analogues as selective DPP-IV inhibitors for the treatment of type-II diabetes.
Mohane Selvaraj Coumar, Chung-Nien Chang, Chiung-Tong Chen, Xin Chen, Chia-Hui Chien, Ting-Yueh Tsai, Jai-Hong Cheng, Hsin-Yi Wu, Chia-Hung Han, Ssu-Hui Wu, Yu-Wen Huang, Tsu Hsu, Li-Jen Hsu, Yu-Sheng Chao, Hsing-Pang Hsieh, Weir-Torn Jiaang
Index: Bioorg. Med. Chem. Lett. 17(5) , 1274-9, (2007)
Full Text: HTML
Abstract
Based on the structures of NVP-DPP728 (1) and NVP-LAF237 (Vildagliptin, 2), three series of DPP-IV inhibitors were synthesized by linking substituted anilines, benzylamines, and phenylethylamines to (2S)-cyanopyrrolidine through a linker. More than 20 compounds were evaluated for their in vitro DPP-IV inhibition and selectivity profile over DPP-II, DPP8, and FAP enzymes. Selected compounds 5f and 7i showed in vivo plasma DPP-IV inhibition and inhibited glucose excursion in OGTT after oral administration in Wistar rats. Compound 5f (DPP-IV IC50 = 116 nM) has the potential for development as antidiabetic agent.
Related Compounds
Related Articles:
2014-08-01
[J. Pharmacol. Exp. Ther. 350(2) , 273-89, (2014)]
2007-03-01
[Appl. Microbiol. Biotechnol. 74(3) , 535-9, (2007)]
2005-01-01
[Biomacromolecules 6(6) , 3380-7, (2005)]
2009-04-01
[Biotechnol. J. 4(4) , 510-6, (2009)]
2001-04-23
[Carbohydr. Res. 331(4) , 439-44, (2001)]